Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Beth

Latest drug approved for migraine prevention will struggle to compete in a crowded market space

Following the news that the Food and Drug Administration (FDA) has approved Vyepti for the prevention of migraines in adults, Philippa Salter, Neurology and Ophthalmology Analyst at GlobalData, a leading data and analytics company, offers her view: “Vyepti becomes the latest FDA approved drug for prevention of migraines in adults, following the approval of Amgen’s Aimovig, Eli Lilly’s Emgality and Teva’s Ajovy all of which were approved in the past two years. “In order to stand out in this crowded market Lundbeck are drawing attention to the improved dosing schedule of every 12 weeks for Vyepti, which they hope will give it a competitive advantage over the other available drugs which require dosing every four […]
Read more

Fresh investments in Patriot Defense System illustrate deteriorating security environment for US’s allies

Following the news that Raytheon’s Patriot will receive a US$314m investment from global partners, Nicolas Jouan, Defense Analyst at GlobalData, a leading data and analytics company, offers his view on the context of these investments: “Raytheon’s Patriot investment is excellent news for the US-based company, whose missile systems business was still its highest source of […]
Read more

Groupe PSA on right path with electrification strategy

Groupe PSA has posted a new profitability record in 2019 and the company has highlighted its electrification strategy as key to future prospects.              David Leggett, Automotive Editor at GlobalData, a leading data and analytics company, offers his view: “PSA’s results for 2019 are certainly impressive – it has improved its financial results for six successive […]
Read more

Tech, media and telecoms predictions for 2020

Leading data and analytics company GlobalData has revealed its predictions for 2020 across the technology, media and telecoms (TMT) industry. The company’s latest thematic research report, ‘TMT Predictions 2020’, identifies the top 20 themes impacting the TMT sector this year and, for each theme, offers a series of predictions and identifies the likely winners and losers. […]
Read more

Promising pipeline products anticipated to bolster treatment options for dry eye syndrome

Current treatment options for dry eye syndrome (DES) are limited to artificial tears, mostly on its own for milder forms of DES and in combination with anti-inflammatory and corticosteroid therapies for more severe forms of DES. However, this treatment paradigm is expected to see a significant change in the next ten years thanks to a number of promising therapies currently in pipeline development.    According to GlobalData, there are 52 pipeline products in different stages of development, which include Phase I, II and III products across the nine […]
Read more

RSA cyber conference must tackle growing network risks

The RSA cybersecurity conference, which started in San Francisco yesterday, will discuss the growing number and increasing complexity of threats impacting organizations. High on the agenda will be the security of industrial information technology (IT) and operational technology (OT) networks after news of a ransomware attack on a US natural gas compression facility raised concerns […]
Read more

Ford’s European unit points the way for Ford turnaround

In an exclusive interview with GlobalData, Ford of Europe President Stuart Rowley outlined the unit’s strategy to move from operating at a loss to turning a profit. David Leggett, Automotive Editor at GlobalData, a leading data and analytics company, offers his view: “Ford of Europe’s President Stuart Rowley told GlobalData that there is much to do […]
Read more

US dermatophytic onychomycosis market set to reach $676.4m by 2028

The dermatophytic onychomycosis market is expected to grow from $208.8m in 2018 to $676.4m in 2028 within the US, at a compound annual growth rate (CAGR) of 12.5%, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Dermatophytic Onychomycosis: US Drug Forecast and Market Analysis to 2028’, states that the US dermatophytic […]
Read more

Positive airway pressure devices market to reach $3.5bn by 2028 driven by home non-invasive ventilation

Global market value for positive airway pressure (PAP) devices, currently estimated at $1.8bn, is expected to expand to $3.5bn by 2028, at a compound annual growth rate (CAGR) of 7.7%, according to GlobalData, a leading data and analytics company. The company’s report, ‘Positive Airway Pressure Devices – Anesthesia & Respiratory Devices Market Analysis and Forecast […]
Read more

BAE’s positive performance will be supported by future armoured vehicle deliveries to the US

Following today’s news (Thursday 20th February) that BAE Systems has met growth forecasts; Harry Boneham, Associate Analyst at GlobalData, a leading data and analytics company, offers his view: “BAE Systems has managed to overcome the setback delivered by the slashing of armoured vehicle production for the US Army in its 2021 budget proposal, and future […]
Read more

Most popular infectious diseases tweets in January 2020

From the coronavirus to fighting vaccine sceptics, leading data and analytics company GlobalData lists ten of the most popular tweets on infectious diseases in January 2020, based on data from the company’s Influencer Platform. 1. Laurie Garrett’s tweet on the coronavirus and how to stay safe Laurie Garrett, a former senior fellow of the Council on Foreign Relations, shared an article on the coronavirus and how to stay […]
Read more

Supply-chain concerns deepening for auto industry

Following remarks by Jaguar Land Rover (JLR) chief Dr Ralph Speth suggesting that the company faces a shortage of key components needed for its UK car plants; David Leggett, Automotive Editor at GlobalData, a leading data and analytics company, offers his view: “The news from JLR isn’t surprising. It is an inevitable consequence of the […]
Read more

Pfizer’s Vyndaqel set to achieve blockbuster status in 2021 with new EU approval for expanded use in ATTR-CM

Following today’s news that Pfizer’s rare disease oral drug Vyndaqel (tafamidis) has gained a new European Medicines Agency (EMA) approval for treating adults with wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM); Sarah Elsayed, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “This new approval will dramatically increase the patient pool […]
Read more
1 … 69 70 71 72 73 … 93